FindMyKOL

Michael Rosove, MD

Basic profile

University of California, Los Angeles

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionLos Angeles, CA · WestSpecialtyHematology / OncologyFocusOncology
Last active 2024FindMyKOL type: RegionalLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH funding1985–1985

Michael Rosove is an Oncology physician affiliated with University of California, Los Angeles. OpenAlex indexes 77 publications with 2,783 citations (h-index 21).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
77publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

2,783citations

Citations across these publications.

21h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 1985–1985

Federally funded research awards.

View funding ↓

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • GENZYME CORPORATION
    Program year20221 payment
    $25

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2022)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    71.7%
    Human Immunoglobulin G71.7%
    Immune globulin100%
    Part B, office-administered≥13 patients
  • Metabolism & gastrointestinal

    12.1%
    Serotonin-3 Receptor Antagonist11.6%
    Ondansetron hydrochloride66%Palonosetron hcl35%
    Part B, office-administered≥15 patients
    Corticosteroid0.6%
    Prednisone100%
    Part D<11 patients
  • Sensory organs

    9.8%
    Corticosteroid9.8%
    Dexamethasone sodium phosphate100%
    Part B, office-administered≥17 patients
Where care is delivered (Part B)0.6% facility · 99.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 1985–1985 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”